Pérez-Pitarch Alejandro, Guglieri-López Beatriz, Nacher Amparo, Merino Virginia, Merino-Sanjuán Matilde
a Pharmaceutical and Pharmaceutical Technology Department , University of Valencia , Valencia , Spain.
b Pharmacy Department , University Clinical Hospital of Valencia , Valencia , Spain.
Nutr Cancer. 2017 May-Jun;69(4):555-563. doi: 10.1080/01635581.2017.1299878. Epub 2017 Mar 29.
The etiology of undernourishment in cancer patients is multifactorial: tumor-related mechanisms (such as obstruction, metabolic abnormalities, and functionality changes) in addition to the influence of anticancer therapies, which can induce or worsen undernutrition. The evident role of undernutrition in cancer treatment outcomes suggests the need of considering nutritional status when evaluating anticancer drugs. In order to merge the available data and offer researchers and clinicians a global view of this phenomenon, the present manuscript reviews on a drug-by-drug basis the undernutrition-related pharmacokinetic and pharmacodynamic aspects of anticancer treatments. This review notes interesting trends in the relationship between undernourishment and pharmacokinetics across studies, and indicates that dosing modifications of these drugs may be necessary to optimize chemotherapeutic treatments. Furthermore, this review has compiled evidence regarding undernourishment's capacity of enhancing treatment-related myelosuppression, cardiotoxicity, ototoxicity, neurotoxicity, and malignancies.
除了抗癌治疗的影响(可诱发或加重营养不良)外,还有肿瘤相关机制(如梗阻、代谢异常和功能改变)。营养不良在癌症治疗结果中所起的明显作用表明,在评估抗癌药物时需要考虑营养状况。为了整合现有数据并为研究人员和临床医生提供这一现象的全局观点,本手稿逐药回顾了抗癌治疗中与营养不良相关的药代动力学和药效学方面。本综述指出了各研究中营养不良与药代动力学之间关系的有趣趋势,并表明可能有必要调整这些药物的剂量以优化化疗治疗。此外,本综述收集了有关营养不良增强治疗相关骨髓抑制、心脏毒性、耳毒性、神经毒性和恶性肿瘤能力的证据。